Literature DB >> 21635661

Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.

J Delangue1, N Salez, L Ninove, A Kieffer, C Zandotti, M Seston, B Lina, A Nougairede, R Charrel, A Flahault, X de Lamballerie.   

Abstract

We looked for evidence of antibodies to the 2009 influenza A/H1N1 pandemic virus in panels of sera from individuals living in metropolitan France, obtained either before, during or after the epidemic, using standard haemagglutination inhibition and microneutralization tests. The difference between seroprevalence values measured in post- and pre-epidemic panels was used as an estimate of seroconversion rate in different age groups (23.4% (0-24 years, age-group 0); 16.5% (25-34); 7.9% (35-44); 7.2% (45-54); 1.6% (55-64); and 3.1% (>65)), confirming that the distribution of cases in different age groups was similar to that of the seasonal H1N1 virus. During the pre-pandemic period low-titre cross-reactive antibodies were present in a large proportion of the population (presumably acquired against seasonal H1N1) whereas cross-reactive antibodies were detected in individuals over the age of 65 years with significantly higher prevalence and serological titres (presumably acquired previously against Spanish flu-related H1N1 strains). Clinical data and analysis of post-pandemic seroprevalence showed that few of these latter patients were infected by the influenza virus during the epidemic. In contrast, the majority of both clinical cases and seroconversions were recorded in the 0-24 age group and a global inverse relationship between prevalence of antibodies to pH1N1 in the pre-pandemic period and rate of seroconversion was observed amongst age groups. Our results emphasize the complex relationships involved in antigenic reactivity to pandemic and seasonal H1N1 viral antigens; hence the difficulty in distinguishing between low-titre specific and cross-reactive antibodies, establishing precise seroprevalence numbers and fully understanding the relationship between previous immunity to seasonal viruses and protection against the novel variant.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21635661     DOI: 10.1111/j.1469-0691.2011.03545.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  13 in total

1.  Antibody prevalence to the 2009 pandemic influenza A (H1N1) virus in Germany: geographically variable immunity in winter 2010/2011.

Authors:  Anne Hackenberg; Gökhan Arman-Kalcek; Jens Hiller; Gülsah Gabriel
Journal:  Med Microbiol Immunol       Date:  2012-06-10       Impact factor: 3.402

2.  Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children.

Authors:  Nitin Verma; Milena Dimitrova; Donald M Carter; Corey J Crevar; Ted M Ross; Hana Golding; Surender Khurana
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 3.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

4.  Transmission characteristics of the 2009 H1N1 influenza pandemic: comparison of 8 Southern hemisphere countries.

Authors:  Lulla Opatowski; Christophe Fraser; Jamie Griffin; Eric de Silva; Maria D Van Kerkhove; Emily J Lyons; Simon Cauchemez; Neil M Ferguson
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

5.  Pandemic influenza due to pH1N1/2009 virus: estimation of infection burden in Reunion Island through a prospective serosurvey, austral winter 2009.

Authors:  Koussay Dellagi; Olivier Rollot; Sarah Temmam; Nicolas Salez; Vanina Guernier; Hervé Pascalis; Patrick Gérardin; Adrian Fianu; Nathanael Lapidus; Nadège Naty; Pablo Tortosa; Karim Boussaïd; Marie-Christine Jaffar-Banjee; Laurent Filleul; Antoine Flahault; Fabrice Carrat; Francois Favier; Xavier de Lamballerie
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240

6.  Evaluation of the seroprevalence of influenza A(H1N1) 2009 on a university campus: a cross-sectional study.

Authors:  Shira C Shafir; Kaitlin A O'Keefe; Kimberley I Shoaf
Journal:  BMC Public Health       Date:  2011-12-13       Impact factor: 3.295

7.  Why was the 2009 influenza pandemic in England so small?

Authors:  Ruben J Kubiak; Angela R McLean
Journal:  PLoS One       Date:  2012-02-10       Impact factor: 3.240

8.  Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France.

Authors:  Angie Bone; Jean-Paul Guthmann; Azzedine Assal; Dominique Rousset; Armelle Degeorges; Pascal Morel; Martine Valette; Vincent Enouf; Eric Jacquot; Bertrand Pelletier; Yann Le Strat; Josiane Pillonel; Laure Fonteneau; Sylvie van der Werf; Bruno Lina; Pierre Tiberghien; Daniel Lévy-Bruhl
Journal:  PLoS One       Date:  2012-03-22       Impact factor: 3.240

9.  Factors associated with post-seasonal serological titer and risk factors for infection with the pandemic A/H1N1 virus in the French general population.

Authors:  Nathanael Lapidus; Xavier de Lamballerie; Nicolas Salez; Michel Setbon; Rosemary M Delabre; Pascal Ferrari; Nanikaly Moyen; Marie-Lise Gougeon; Frédéric Vely; Marianne Leruez-Ville; Laurent Andreoletti; Simon Cauchemez; Pierre-Yves Boëlle; Eric Vivier; Laurent Abel; Michaël Schwarzinger; Michèle Legeas; Pierre Le Cann; Antoine Flahault; Fabrice Carrat
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

10.  2009 A(H1N1) seroconversion rates and risk factors among the general population in Vientiane Capital, Laos.

Authors:  Alexia Kieffer; Phimpha Paboriboune; Pascal Crépey; Bruno Flaissier; Vimalay Souvong; Nicolas Steenkeste; Nicolas Salez; François-Xavier Babin; Christophe Longuet; Fabrice Carrat; Antoine Flahault; Xavier de Lamballerie
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.